AHA PREVENT Cardiovascular Risk Calculator

Understanding the Three PREVENT Outcomes

The most common source of confusion with PREVENT is that it does not produce a single risk number. It estimates three related but distinct outcomes, and the calculator above presents each on its own tab.

Total CVD is PREVENT’s primary outcome and the broadest: it combines atherosclerotic disease and heart failure into a single estimate of any major cardiovascular event. ASCVD narrows this to atherosclerotic events only — myocardial infarction, coronary death, and stroke — and is the estimate that guideline statin thresholds are built around. Heart failure is reported on its own because its risk is shaped strongly by metabolic and renal factors rather than by cholesterol, and it is not used to decide statin therapy.

Because Total CVD includes heart failure, it is always the largest of the three numbers. Applying the statin risk thresholds to the Total CVD figure rather than the ASCVD figure will overestimate the indication for treatment, so the ASCVD tab is the one to use for that decision.

What Is the PREVENT Calculator?

PREVENT is a cardiovascular risk prediction model developed by the American Heart Association and published in Circulation in 2024 (Khan SS et al.). The 2026 ACC/AHA Guideline on the Management of Dyslipidemia recommends the PREVENT equations as the preferred tool for estimating cardiovascular risk in adults aged 30–79 years, replacing the older Pooled Cohort Equations used in previous guidelines.

The equations were derived from pooled data on more than six million adults across contemporary US cohorts, giving improved calibration and accuracy compared with earlier models. They are race-free and, uniquely, include both 10-year and 30-year estimates.

10-Year and 30-Year Risk

For every outcome, PREVENT estimates both 10-year and 30-year risk. The calculator shows the 30-year estimate for patients aged 30–59, where it is most informative. In younger adults a 10-year figure can look reassuringly low while lifetime burden is substantial, and the 30-year estimate helps frame that longer horizon. The 30-year models are not applied above age 59.

How PREVENT Differs From the Traditional ASCVD Calculator

The PREVENT equations were designed to address several limitations of the Pooled Cohort Equations (PCE) used in earlier ASCVD calculators. They remove race as a predictor, add kidney function (eGFR) and body mass index as core variables, extend the age range down to 30 years, and add heart failure as an outcome. They also allow optional refinement with HbA1c and urine albumin-to-creatinine ratio when those values are available.

One practical nuance worth noting: in the base model, BMI contributes to the heart-failure estimate but carries no weight for the ASCVD or Total CVD estimates. A high BMI will therefore move the heart-failure number without changing the atherosclerotic figures.

Because cardiovascular event rates have fallen over the past two decades, the older PCE tended to overestimate risk in contemporary populations. PREVENT is recalibrated to current event rates, so for the same patient it often produces a lower numerical estimate than the PCE. This reflects better calibration rather than genuinely lower risk.

2026 Risk Categories (ASCVD)

The risk thresholds used for treatment decisions apply to the PREVENT 10-year ASCVD estimate. The 2026 ACC/AHA dyslipidemia guideline defines:

• Low risk: <3% — lifestyle counselling.
• Borderline risk: 3% to <5% — moderate-intensity statin may be reasonable after clinician–patient discussion.
• Intermediate risk: 5% to <10% — at least moderate-intensity statin recommended; high-intensity may be considered toward the upper end.
• High risk: ≥10% — high-intensity statin recommended to achieve ≥50% LDL-C reduction.

Although these percentages are lower than the traditional PCE thresholds (5%, 7.5%, 20%), they generally identify similar groups for treatment because PREVENT corrects the overestimation seen with the older equations. Risk estimation remains stepwise: calculate with PREVENT, personalise with risk-enhancing factors, and reclassify with selective coronary artery calcium (CAC) testing where uncertainty remains.

Kidney and Metabolic Risk Factors

Reduced eGFR and albuminuria are independent predictors of cardiovascular events, with risk rising progressively as kidney function declines below 60 mL/min/1.73 m². BMI captures metabolic risk not reflected by cholesterol and blood pressure alone, and in people with diabetes, HbA1c adds prognostic precision within that group. These reflect the broader Cardiovascular-Kidney-Metabolic (CKM) framework linking cardiovascular disease, chronic kidney disease, diabetes, and obesity — and make PREVENT particularly useful in these populations, where traditional ASCVD calculators may underrepresent risk.

When PREVENT Is Most Helpful

PREVENT is the guideline-preferred tool for primary-prevention risk estimation in adults aged 30–79. It is especially useful in people with diabetes or prediabetes, chronic kidney disease, metabolic syndrome or obesity, and in younger adults (30–40) who fall outside the traditional ASCVD calculator range. Where coronary artery calcium data is available, the MESA CAC calculator can refine risk further with direct imaging evidence of coronary atherosclerosis.